• SHARE

Japan’s health ministry gave fast-track approval for Pfizer’s oral drug for COVID-19 on Thursday, as the government hopes a new treatment option will help alleviate the burden on a health care system that’s approaching the brink of collapse amid the omicron-driven sixth wave.

The drug is the second oral antiviral pill that has received the panel’s approval for COVID-19 treatment after Merck & Co.’s molanupiravir. The approval came following the ministry panel’s approval earlier on Thursday.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.

SUBSCRIBE NOW

PHOTO GALLERY (CLICK TO ENLARGE)